Page 3 - Sanket Koul

Brazil rejects Dr Reddy's, Cipla GLP-1 generics on technical grounds

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Ammonia shortage: DoP to seek support from MoPNG, Fertilisers Dept

The Department of Pharmaceuticals plans to approach MoPNG and the Fertilisers Department to secure ammonia supplies for drugmakers amid shortages triggered by West Asia tensions

MNC medtech firms seek changes in local content norms for procurement

Multinational medtech firms have urged the Centre to revise local content calculations under PPOs, proposing inclusion of R&D and maintenance costs to widen eligibility in tenders

Centre revises DCGI recruitment rules, raises age limit to widen pool

The Centre has raised the age limit and broadened eligibility norms for appointing the Drug Controller General of India to address a shortage of qualified candidates

Lohia Worldspace eyes Delhi market entry, expansion in Moradabad in FY27

Lohia Worldspace plans Delhi entry with a Kirti Nagar high-rise and expands in Moradabad, targeting multiple projects and investments in FY27

Max Healthcare to add 1,200 beds in FY27, says Chairman Abhay Soi

Max Healthcare plans to expand capacity to 6,500 beds by FY27 and boost medical tourism through overseas offices and new facilities, including a 400-bed tower in Delhi

West Asia war drags India's March drug exports for first time in 3 years

On an FY basis, India's pharma exports remained flat at $31.11 billion in FY26, a 2.13 per cent rise from $30.47 billion in FY25

Signature Global to invest ₹2,890 crore in Tonino Lamborghini project

Signature Global has partnered Tonino Lamborghini to develop a branded residences project in Gurugram, with a planned investment of Rs 2,890 crore and expected GDV of Rs 4,000 crore

India a very high-priority market, Fortis primary growth vehicle: IHH CEO

IHH Healthcare eyes aggressive India expansion via Fortis, focusing on bed capacity, clusters, and ambulatory care amid strong healthcare demand

Strait of Hormuz crisis poses threat to India's luxury housing market

Developers stare at delayed imports of key materials, higher costs of imports and potential delay in construction timelines

Parliamentary panel pulls up HealthMin over drug scheme funding gaps

Panel flags funding discontinuity in drug regulation scheme, urges swift SSDRS 2.0 approval and decentralisation of medical device clearances to ease bottlenecks and improve oversight

Medtech industry split over Centre's move on standard device testing fees

Medtech firms are split over draft norms on standardised testing fees, with some backing transparency and others warning of higher compliance burden for low-risk devices

Drug regulator may retain GMP relaxations in Schedule M for select products

DTAB recommends continuing GMP exemptions under revised Schedule M for disinfectants, medical gases and gelatin capsules, citing limited relevance of strict norms

CDSCO moves to fast-track foreign drug import approvals, cut delays

Regulator plans to cut delays by allowing direct submission of Form 40 applications to DCGI, aiming to improve efficiency in drug import approvals

Semaglutide generics hit Mounjaro sales, market share after patent expiry

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Dalcore to invest ₹500 cr in first YOO-branded residences in North India

Developer eyes a topline of Rs 1,450 cr, with units priced at Rs 10 cr and above

Signature Global reports 5% drop in Q4 sales bookings on weak demand

Realty firm reports decline in Gurugram demand as FY26 bookings fall 20% to Rs 8,220 crore, missing guidance, even as average realisation improves on premiumisation

Max Healthcare acquires 58.4% stake in Kalinga Hospital for ₹300 crore

Max Healthcare enters eastern India with Kalinga Hospital acquisition, adding 250 beds and expanding its network through a Rs 300 crore deal

Max Estates FY26 pre-sales dip slightly despite strong Q4 demand

Developer reports marginal dip in annual pre-sales, but Q4 bookings surge on new launches, with strong pipeline and steady collections supporting growth outlook